PPT-Prolonging the Effects of Factor IX Replacement Therapy in Hemophilia B

IntroductionOverview IntroductionOverview cont Importance of Prophylaxis and Limitations on Its Application in Hemophilia B Key Unmet Need in Hemophilia B Reducing Patient Burden of Disease. Nairobi, Kenya. June 24, 2013. Jim Munn, R.N., M.S.. Program Nurse Coordinator. University of Michigan HTC. Ann Arbor, MI, USA. Chair – WFH Nursing . Committee. Acknowledgement. : . Slides 20,21, 23-28 . 1. Hemophilia A and B: . Disease Differences and the . Use of Prophylactic Therapy. Anna Chalmers, MD . Rush University Medical Center, Chicago, Illinois. A REPORT FROM THE 65. TH. ANNUAL MEETING OF THE NATIONAL HEMOPHILIA FOUNDATION (NHF 2013) . By: Nam-Y7. Hemophilia was first recognized by the Jews, but not officially named even in the ancient times. . In the 2. nd. century AD, the Talmud, a Jewish collection of Rabbinical writings said that the boys did not have to be circumcised if two brothers died of the disease. In 1800s, it became known as the Royal Disease because many people of royal families died or got the disease. Queen Victoria got Hemophilia but she survived. Alexei, the heir apparent to the Russian royal family, suffered from Hemophilia. In 1950s, the first treatment to hemophilia appeared. It was in a type called “fresh frozen plasma”. Nowadays, we are marching towards a cure but there are two treatments. One is called “gene therapy” and the other is called “Recombinant therapy”. A treatment for hemophilia is replacing old blood clots with new ones.. 2012. Michael Recht, MD, PhD. Director, The Hemophilia Center. Oregon Health & Science University. Disclosures. Research funding directly to OHSU from. NovoNordisk. Baxter. Biogen. Idec. Pfizer. Sex-linked inheritance; almost all patients male. Female carriers may have mild symptoms. Most bleeding into joints, muscles; mucosal and CNS bleeding uncommon. Severity inversely proportional to factor level. WVNHF. Amber Tichnell, Executive Director. Hemophilia and other bleeding disorders. The human body is made up of several clotting factors – Factors 1 through 13 plus Von . Willebrand. Factor. A person can have deficiencies in any of these factors. Jaimes. . and Daniel Barnett . Name of disorder. The name of our disorder is hemophilia. An alternate name for it is . haemophilia. . The pronunciation is . he·mo·phil·ia. . The name means love of blood and was chosen by . Hemophilia A. Also known as Factor VIII Deficiency is the most common type of hemophilia. It is a disorder of your blood-clotting system. Clotting is the process which your blood changes from a liquid to a solid state. Andrew J. . Costandi. , MD, MMM . Children’s Hospital Los Angeles. USC Keck School of Medicine. Faculty Disclosures. None. Learning Objectives. Upon completion of this activity, participants will be able to:. Mehran Karimi MD. Tehran, September 14, 2017. Agenda. Background. Causes of bleeding and Clinical manifestations. Classification of coagulation disorders in neonates. Primary investigation and diagnostic evaluation. EALTH up in the reference center for hemostatic disor-The present study reports the cost-effective-International Hemophilia Training Center, Fac-University, Bangkok, Thailand.MATERIALS AND METHODSfami . Chelsea Marion, MD. 1,4. , Oluwaseun Odewole, MD, MPH. 2,4. , Sheila Goel, MD. 3,4. . 1. Dept. of Pediatrics, Morehouse School of Medicine, Atlanta, GA. . 2. Dept. of Family Medicine, Morehouse School of Medicine, Atlanta, GA. . Robin Reid, MD. Clinical Director, Mary M Gooley Hemophilia Center. Hematologist and Medical Oncologist, Rochester Regional Health. July . 2021. Outline. History of the Mary M Gooley Hemophilia Treatment Center. Lizheng Shi, PhD, . MsPharm. Regents Professor and Interim Chair. Department of Health policy and Management. School of Public Health and Tropical Medicine. Funded by BioMarin Pharmaceutical, which provided input into study design..